Cargando…
Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
BACKGROUND: Evaluation of secondary stroke prevention in low and middle-income countries remains limited. This study assessed the prescription of secondary preventive drugs among ischemic stroke patients upon hospital discharge in Malaysia and identified factors related to the prescribing decisions....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701494/ https://www.ncbi.nlm.nih.gov/pubmed/29169331 http://dx.doi.org/10.1186/s12883-017-0984-1 |
_version_ | 1783281354302029824 |
---|---|
author | Hwong, Wen Yea Abdul Aziz, Zariah Sidek, Norsima Nazifah Bots, Michiel L. Selvarajah, Sharmini Kappelle, L. Jaap Sivasampu, Sheamini Vaartjes, Ilonca |
author_facet | Hwong, Wen Yea Abdul Aziz, Zariah Sidek, Norsima Nazifah Bots, Michiel L. Selvarajah, Sharmini Kappelle, L. Jaap Sivasampu, Sheamini Vaartjes, Ilonca |
author_sort | Hwong, Wen Yea |
collection | PubMed |
description | BACKGROUND: Evaluation of secondary stroke prevention in low and middle-income countries remains limited. This study assessed the prescription of secondary preventive drugs among ischemic stroke patients upon hospital discharge in Malaysia and identified factors related to the prescribing decisions. METHODS: From Malaysian National Stroke Registry, we included patients with non-fatal ischemic stroke. Prescriptions of antiplatelet, anticoagulants, antihypertensive drugs and lipid-lowering drugs were assessed. Multi-level logistic regressions were performed to determine the relation between potential factors and drug prescriptions. RESULTS: Of 5292 patients, 48% received antihypertensive drugs, 88.9% antiplatelet and 88.7% lipid-lowering drugs upon discharge. Thirty-three percent of patients with an indication for anticoagulants (n = 391) received it. Compared to patients <=50 years, patients above 70 years were less likely to receive antiplatelet (OR: 0.72, 95% CI: 0.50–1.03), lipid-lowering drugs (OR: 0.66, 95% CI: 0.45–0.95) and anticoagulants (OR: 0.27, 95% CI: 0.09–0.83). Patients with moderate to severe disability upon discharge had less odds of receiving secondary preventive drugs; an odds ratio of 0.57 (95% CI: 0.45–0.71) for antiplatelet, 0.86 (95% CI: 0.75–0.98) for antihypertensive drugs and 0.78 (95% CI: 0.63–0.97) for lipid-lowering drugs in comparison to those with minor disability. Having prior specific comorbidities and drug prescriptions significantly increased the odds of receiving these drugs. No differences were found between sexes and ethnicities. CONCLUSIONS: Prescription of antihypertensive drugs and anticoagulants among ischemic stroke patients in Malaysia were suboptimal. Efforts to initiate regular clinical audits to evaluate the uptake and effectiveness of secondary preventive strategies are timely in low and middle-income settings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12883-017-0984-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5701494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57014942017-12-04 Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry Hwong, Wen Yea Abdul Aziz, Zariah Sidek, Norsima Nazifah Bots, Michiel L. Selvarajah, Sharmini Kappelle, L. Jaap Sivasampu, Sheamini Vaartjes, Ilonca BMC Neurol Research Article BACKGROUND: Evaluation of secondary stroke prevention in low and middle-income countries remains limited. This study assessed the prescription of secondary preventive drugs among ischemic stroke patients upon hospital discharge in Malaysia and identified factors related to the prescribing decisions. METHODS: From Malaysian National Stroke Registry, we included patients with non-fatal ischemic stroke. Prescriptions of antiplatelet, anticoagulants, antihypertensive drugs and lipid-lowering drugs were assessed. Multi-level logistic regressions were performed to determine the relation between potential factors and drug prescriptions. RESULTS: Of 5292 patients, 48% received antihypertensive drugs, 88.9% antiplatelet and 88.7% lipid-lowering drugs upon discharge. Thirty-three percent of patients with an indication for anticoagulants (n = 391) received it. Compared to patients <=50 years, patients above 70 years were less likely to receive antiplatelet (OR: 0.72, 95% CI: 0.50–1.03), lipid-lowering drugs (OR: 0.66, 95% CI: 0.45–0.95) and anticoagulants (OR: 0.27, 95% CI: 0.09–0.83). Patients with moderate to severe disability upon discharge had less odds of receiving secondary preventive drugs; an odds ratio of 0.57 (95% CI: 0.45–0.71) for antiplatelet, 0.86 (95% CI: 0.75–0.98) for antihypertensive drugs and 0.78 (95% CI: 0.63–0.97) for lipid-lowering drugs in comparison to those with minor disability. Having prior specific comorbidities and drug prescriptions significantly increased the odds of receiving these drugs. No differences were found between sexes and ethnicities. CONCLUSIONS: Prescription of antihypertensive drugs and anticoagulants among ischemic stroke patients in Malaysia were suboptimal. Efforts to initiate regular clinical audits to evaluate the uptake and effectiveness of secondary preventive strategies are timely in low and middle-income settings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12883-017-0984-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-23 /pmc/articles/PMC5701494/ /pubmed/29169331 http://dx.doi.org/10.1186/s12883-017-0984-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hwong, Wen Yea Abdul Aziz, Zariah Sidek, Norsima Nazifah Bots, Michiel L. Selvarajah, Sharmini Kappelle, L. Jaap Sivasampu, Sheamini Vaartjes, Ilonca Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry |
title | Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry |
title_full | Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry |
title_fullStr | Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry |
title_full_unstemmed | Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry |
title_short | Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry |
title_sort | prescription of secondary preventive drugs after ischemic stroke: results from the malaysian national stroke registry |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701494/ https://www.ncbi.nlm.nih.gov/pubmed/29169331 http://dx.doi.org/10.1186/s12883-017-0984-1 |
work_keys_str_mv | AT hwongwenyea prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT abdulazizzariah prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT sideknorsimanazifah prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT botsmichiell prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT selvarajahsharmini prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT kappelleljaap prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT sivasampusheamini prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry AT vaartjesilonca prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry |